TY - STD TI - Cooke G, Andrieux-Meyer I, Applegate T, et al. Lancet Commission: Accelerating the elimination of viral hepatitis. Lancet Gastroenterol Hepatol. 2019 (In press). ID - ref1 ER - TY - STD TI - Global health sector strategy on viral hepatitis, 2016–2021: towards ending viral hepatitis. Geneva: World Health Organization; 2016. Available at: http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf. UR - http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf ID - ref2 ER - TY - JOUR AU - Lazarus, J. V. AU - Safreed-Harmon, K. AU - Thursz, M. R. PY - 2018 DA - 2018// TI - The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations JO - Semin Liver Dis VL - 38 UR - https://doi.org/10.1055/s-0038-1627456 DO - 10.1055/s-0038-1627456 ID - Lazarus2018 ER - TY - JOUR AU - Tozun, N. AU - Ozdogan, O. AU - Cakaloglu, Y. PY - 2015 DA - 2015// TI - Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study JO - Clin Microbiol Infect VL - 21 UR - https://doi.org/10.1016/j.cmi.2015.06.028 DO - 10.1016/j.cmi.2015.06.028 ID - Tozun2015 ER - TY - JOUR AU - Tosun, S. PY - 2013 DA - 2013// TI - The changing viral hepatitis epidemiology in our country JO - ANKEM Derg VL - 27 ID - Tosun2013 ER - TY - STD TI - Türkiye viral hepatit önleme ve kontrol programı (2018–2023). 2018. https://dosyahastane.saglik.gov.tr/Eklenti/62428,viral-hematit-onlemepdf.pdf?0&_tag1=5A894E52BB71C16366CF1098BBA11F1A4D2012BF. UR - https://dosyahastane.saglik.gov.tr/Eklenti/62428 ID - ref6 ER - TY - JOUR PY - 2017 DA - 2017// TI - Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study JO - Lancet Gastroenterol Hepatol VL - 2 UR - https://doi.org/10.1016/S2468-1253(17)30045-6 DO - 10.1016/S2468-1253(17)30045-6 ID - ref7 ER - TY - JOUR AU - Blach, S. AU - Zeuzem, S. AU - Manns, M. PY - 2016 DA - 2016// TI - Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study JO - Lancet Gastroenterol Hepatol VL - 2 UR - https://doi.org/10.1016/S2468-1253(16)30181-9 DO - 10.1016/S2468-1253(16)30181-9 ID - Blach2016 ER - TY - JOUR AU - Irvem, A. AU - Ozdul, K. AU - Kadan, A. PY - 2017 DA - 2017// TI - Hepatitis C seropositivity and distribution of HCV genotypes JO - J Clin Anal Med VL - 8 UR - https://doi.org/10.4328/JCAM.4926 DO - 10.4328/JCAM.4926 ID - Irvem2017 ER - TY - STD TI - Tabak F, Cuvalci NO, Kurtaran B, et al. Turkiye’de Direkt Etkili Antiviral Ajanlari Kullanan Kornik Hepatit C Hastalarinin Demografik Ve Klinik Ozellikleri. E Poster −145. Ulusal Gastroenteroloji Haftasi. April 2017. Antalya. ID - ref10 ER - TY - STD TI - Aygen B et al. Klimik association. Management and treatment of special populations with HBV and HCV symposia. Presentation on dated 19.10.2017 Istanbul Turkey, 19 Oct 2017. https://www.klimik.org.tr/wp-content/uploads/2017/09/DAMAR-%C4%B0%C3%87%C4%B0-%C4%B0LA%C3%87-BA%C4%9EIMLILARINDA-HEPAT%C4%B0T-C-%C4%B0NFEKS%C4%B0YONU-Bilgehan-AYGEN.pdf. PowerPoint presentation. UR - https://www.klimik.org.tr/wp-content/uploads/2017/09/DAMAR-%C4%B0%C3%87%C4%B0-%C4%B0LA%C3%87-BA%C4%9EIMLILARINDA-HEPAT%C4%B0T-C-%C4%B0NFEKS%C4%B0YONU-Bilgehan-AYGEN.pdf ID - ref11 ER - TY - STD TI - Demir M, Danis N, Kani HT, et al. Real world data on safety and efficacy of ledipasvir + sofosbuvir ± RBV, ombitasvir/paritaprevir/ritonavir ± dasabuvir ± RBV combination therapy for chronic hepatitis C: a Turkey experience. APASL Single Topic Symposium. 2018;S-001. ID - ref12 ER - TY - JOUR AU - Yamazhan, T. AU - Tasova, Y. AU - Candevir, A. U. PY - 2018 DA - 2018// TI - Profile of chronic HCV infection in Turkey: Results of multi-centered HEP-C Turkey study JO - Mediterr J Infect, Microb Antimicrob VL - 8 ID - Yamazhan2018 ER - TY - JOUR AU - Kizilates, F. AU - Berk, H. AU - Coban, M. PY - 2016 DA - 2016// TI - Seroprevalence of hepatitis B and C virus in patients who undergo hemodialysis in Antalya province, Turkey JO - Asian Biomed VL - 10 ID - Kizilates2016 ER - TY - JOUR AU - Korkmaz, P. AU - Çağlan Çevik, F. AU - Aykın, N. PY - 2014 DA - 2014// TI - Hepatitis B virus and hepatitis C virus seroprevalence in hemodialysis patients in Eskişehir Yunus Emre State Hospital JO - Viral Hepatitis J VL - 20 UR - https://doi.org/10.4274/vhd.47955 DO - 10.4274/vhd.47955 ID - Korkmaz2014 ER - TY - JOUR AU - Arabaci, F. AU - Oldacay, M. PY - 2009 DA - 2009// TI - Hepatitis B, C seroprevalance and chronicity rates for hepatitis in patients treated by different dialysis centers in Canakkale Province, Turkey JO - Turkish Bull Hyg Exp Biol VL - 66 ID - Arabaci2009 ER - TY - JOUR AU - Kaplan, O. AU - Bakici, M. Z. AU - Celik, C. PY - 2013 DA - 2013// TI - The seropositivity of HBsAg and HCV of the patients from Cumhuriyet University Research and Practice Hemodialysis Unit JO - Viral Hepatitis J VL - 19 UR - https://doi.org/10.4274/Vhd.88597 DO - 10.4274/Vhd.88597 ID - Kaplan2013 ER - TY - STD TI - Ministry of Health, Turkish Society of Nephrology. Registry of the nephrology, dialysis and transplantation in Turkey: Registry 2016. Ankara: Turkish Society of Nephrology. p. 2017. Available at: http://tsn.org.tr/folders/file/2016_REGISTRY.pdf. UR - http://tsn.org.tr/folders/file/2016_REGISTRY.pdf ID - ref18 ER - TY - BOOK PY - 2015 DA - 2015// TI - Report on the annual global survey 2014 PB - World Federation of Hemophilia CY - Montreal, Quebec ID - ref19 ER - TY - STD TI - Turkish Society of Hematology. Beta thalassemia diagnosis and treatment guideline. Available at: http://www.thd.org.tr/thdData/userfiles/file/Talasemi-_26_04_2011%5B1%5D%5B1%5D.pdf [In Turkish]. UR - http://www.thd.org.tr/thdData/userfiles/file/Talasemi-_26_04_2011%5B1%5D%5B1%5D.pdf ID - ref20 ER - TY - STD TI - Şanlı C, Albayrak M, Nakpo F, Gümrük F, et al. Sık Kan Transfüzyonu Alan Beta-Talasemi Majörlü Hastalarda Hepatit B, Hepatit C ve Hepatit G Virüs Sıklığı. [The frequency of hepatitis B, hepatitis C and hepatitis G virus in patients with beta-thalassemia major who receive frequent blood transfusion.] Viral Hepatit Dergisi. 2005;10(3):150–157. Available at: http://cms.galenos.com.tr/Uploads/Article_6588/150-157.pdf. UR - http://cms.galenos.com.tr/Uploads/Article_6588/150-157.pdf ID - ref21 ER - TY - STD TI - Şahi̇n A, Yıldız Yildirmak Z, Emin Bulut M, et al. ÇOK sayida transfüzyon alan talasemi majörlü hastalarda hepatit B, hepatit C ve HIV (İNSAN İMMÜN YETMEZLİK VİRÜSÜ) SIKLIĞI. ANKEM Derg. 2018;32:9–16. Available at: ). ID - ref22 ER - TY - STD TI - Tabak F, Cuvalci NO, Kurtaran B, et al. Turkiye’de Direkt Etkili Antiviral Ajanlari Kullanan Kornik Hepatit C Hastalarinin Demografik Ve Klinik Ozellikleri. E Poster −145. Ulusal Gastroenteroloji Haftasi. April 2017, Antalya. ID - ref23 ER - TY - STD TI - Kara I, A. et al. hepatitis prevalence in Turkey, a systematic review. Presented at KLIMIK Assoc. viral hepatitis working group presentation presented on date 21.01.2017 Bursa, Turkey. ID - ref24 ER - TY - JOUR AU - Başkol, M. AU - Zaimoğlu, A. AU - Mazıcıoğlu, M. M. PY - 2009 DA - 2009// TI - Prevalence of hepatitis C virus infection and possible risk factors in Sulusaray, Nevşehir JO - Turk Aile Hek Derg VL - 13 UR - https://doi.org/10.2399/tahd.09.081 DO - 10.2399/tahd.09.081 ID - Başkol2009 ER - TY - BOOK PY - 2017 DA - 2017// TI - Turkey: country drug report 2017 PB - EMCDDA CY - Luxembourg ID - ref26 ER - TY - JOUR AU - Keten, D. AU - Emin Ova, M. AU - Sirri Keten, H. PY - 2016 DA - 2016// TI - The prevalence of hepatitis B and C among prisoners in Kahramanmaras, Turkey JO - Jundishapur J Microbiol VL - 9 UR - https://doi.org/10.5812/jjm.31598 DO - 10.5812/jjm.31598 ID - Keten2016 ER - TY - JOUR AU - Heffernan, A. AU - Cooke, G. S. AU - Nayagam, S. AU - Thursz, M. AU - Hallet, T. B. PY - 2019 DA - 2019// TI - Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model JO - Lancet VL - 393 UR - https://doi.org/10.1016/S0140-6736(18)32277-3 DO - 10.1016/S0140-6736(18)32277-3 ID - Heffernan2019 ER - TY - JOUR AU - Cure, S. AU - Guerra, I. AU - Dusheiko, G. PY - 2015 DA - 2015// TI - Cost-effectiveness of sofosbovir for the treatment of chronic hepatitis C-infected patients JO - J Viral Hepat VL - 22 UR - https://doi.org/10.1111/jvh.12409 DO - 10.1111/jvh.12409 ID - Cure2015 ER - TY - STD TI - Cipriano LE. Goldhaber-Fiebert. Population health and cost-effectiveness implications of a “Treat All” recommendation for HCV: A review of the model-based evidence. MDM Policy Pract. 2018:1–27. ID - ref30 ER - TY - JOUR AU - Ormeci, N. AU - Akarca, U. AU - Aladag, M. PY - 2014 DA - 2014// TI - Estimation of hepatitis C cots in Turkey via expert opinion: Delphi panel JO - Value Health VL - 17 UR - https://doi.org/10.1016/j.jval.2014.03.222 DO - 10.1016/j.jval.2014.03.222 ID - Ormeci2014 ER - TY - JOUR AU - Lazarus, J. V. AU - Pèricas, J. M. AU - Picchio, C. PY - 2019 DA - 2019// TI - We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade JO - J Intern Med VL - 286 UR - https://doi.org/10.1111/joim.12972 DO - 10.1111/joim.12972 ID - Lazarus2019 ER - TY - BOOK PY - 2016 DA - 2016// TI - Turkish Transplant Foundation ID - ref33 ER - TY - JOUR AU - Evren, C. AU - Bilici, R. AU - Ucbilek, E. PY - 2017 DA - 2017// TI - A call to action for the prevention of hepatitis C infection among intravenous drug users in Turkey JO - Dusunen Adam J Psychiatry Neurol Sci VL - 30 UR - https://doi.org/10.5350/DAJPN20173004001 DO - 10.5350/DAJPN20173004001 ID - Evren2017 ER - TY - JOUR AU - Lazarus, J. V. AU - Wiktor, S. AU - Colombo, M. PY - 2017 DA - 2017// TI - On behalf of the EASL international Liver Foundation. Micro-elimination – a path to global elimination of hepatitis C JO - J Hepatol VL - 67 UR - https://doi.org/10.1016/j.jhep.2017.06.033 DO - 10.1016/j.jhep.2017.06.033 ID - Lazarus2017 ER - TY - JOUR AU - Piccinino, F. AU - Sagnelli, E. AU - Pasquale, G. AU - Giusti, G. PY - 1986 DA - 1986// TI - Complications following percutaneous liver biopsy: a multicentre retrospective study on 68,276 biopsies JO - J Hepatol VL - 2 UR - https://doi.org/10.1016/S0168-8278(86)80075-7 DO - 10.1016/S0168-8278(86)80075-7 ID - Piccinino1986 ER - TY - JOUR AU - Papatheordorides, G. AU - Hatzakis, A. AU - Cholongitas, E. PY - 2018 DA - 2018// TI - Hepatitis C: the beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe JO - J Viral Hepat VL - 25 UR - https://doi.org/10.1111/jvh.12875 DO - 10.1111/jvh.12875 ID - Papatheordorides2018 ER - TY - JOUR AU - Safreed-Harmon, K. AU - Blach, S. AU - Aleman, S. PY - 2019 DA - 2019// TI - The consensus hepatitis C cascade of care: standardized reporting to monitor progress toward elimination JO - Clin Infect Dis VL - 69 UR - https://doi.org/10.1093/cid/ciz714 DO - 10.1093/cid/ciz714 ID - Safreed-Harmon2019 ER -